Thanks rgc68. I understand from from the latest trial results that it BIT225 is not as effective for HCV as the drugs by Gilead and AbbVie. What's your view on BIT225 as combination therapy for the small proportion of the patient populationfor whom the new generation drugs may not be working? I haven't seen any data to confirm that BIT 225 will be effective in these cases as a combination drug, but have noticed the true believers on HC are keen to push that view.
I'm fast coming to two conclusions - 1. Michelle Miller is the wrong person to lead BIT and these guys have a small window of time to take a shot at HIV.
I stand to lose a packet here, but need to objectively reassess my position. So any objective and scientific views would be gratefully received. Thanks.
Thoughts, page-15
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.7¢ |
Change
-0.011(39.3%) |
Mkt cap ! $15.33M | |||
| Open | High | Low | Value | Volume |
| 2.2¢ | 2.5¢ | 1.7¢ | $374.7K | 18.97M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 1266038 | 1.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.8¢ | 689330 | 2 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| BIT (ASX) Chart |